Medindia

X

Health Tip on Drugs for Children Affected with Hepatitis C

The U.S. Food and Drug Administration (FDA) has approved the use of the directly acting agents (DAAs) sofosbuvir (available as Sovaldi) and the combination of ledipasvir and sofosbuvir (available as Harvoni) for the treatment of hepatitis C in children and adolescents between the ages of 12 to 17 years, thereby increasing the possible number of beneficiaries of this new treatment.
Advertisement
Advertisement
Advertisement
Advertisement